Dr. Duffield on Implications for Immunotherapy in Nasopharyngeal Carcinoma

Video

In Partnership With:

Amy Duffield, MD, PhD, assistant professor of pathology, Johns Hopkins University School of Medicine, member, Johns Hopkins Kimmel Cancer Center, discusses the implications for immunotherapy in nasopharyngeal carcinoma.

Amy Duffield, MD, PhD, assistant professor of pathology, Johns Hopkins University School of Medicine, member, Johns Hopkins Kimmel Cancer Center, discusses the implications for immunotherapy in nasopharyngeal carcinoma.

Nasopharyngeal carcinoma is driven by Epstein-barr virus, and has a relatively poor clinical outcome when patients are treated with cytotoxic chemotherapy or radiotherapy. Duffield says that new therapies, such as immunotherapy, could be beneficial for these patients.

In an analysis of the immunosuppressive tumor microenvironment in nasopharyngeal carcinoma, investigators from Johns Hopkins Medicine aimed to find new combinations of immunotherapies to more successfully treat this neoplasm. Archival specimens of nasopharyngeal carcinoma were collected and characterized in order to hopefully make more effective individualized immunotherapy regimens for patients, Duffield explains.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD